These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12173280)

  • 21. Health care resource utilization and costs of NSAID-induced gastrointestinal toxicity. A population-based study in Switzerland.
    Delcò F; Michetti P; Beglinger C; Fried M; Szucs TD
    Digestion; 2004; 69(1):10-9. PubMed ID: 14755148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A; Ferrandez A
    Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example.
    van Staa TP; Leufkens HG; Zhang B; Smeeth L
    PLoS Med; 2009 Dec; 6(12):e1000194. PubMed ID: 19997499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rofecoxib (Vioxx)--the first of a new generation of NSAIDs.
    MacConnachie AM
    Intensive Crit Care Nurs; 2000 Jun; 16(3):201-2. PubMed ID: 10859630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis.
    Yun HR; Bae SC
    Rheumatol Int; 2005 Jan; 25(1):9-14. PubMed ID: 13680139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonsteroidal antiinflammatory drugs: benefits, risks, and COX-2 selectivity.
    Halverson PB
    Orthop Nurs; 1999; 18(6):21-6; quiz 27-8. PubMed ID: 11062611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Can we treat with modern antirheumatics? Costs of NSAID treatment].
    Bolten WW
    Pharm Unserer Zeit; 2002; 31(2):206-15. PubMed ID: 11977457
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients.
    Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
    Br J Clin Pharmacol; 2001 Aug; 52(2):185-92. PubMed ID: 11488776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NSAIDs-induced gastrointestinal damage. Review.
    Arroyo M; Lanas A
    Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?
    Elliott RA; Hooper L; Payne K; Brown TJ; Roberts C; Symmons D
    Rheumatology (Oxford); 2006 May; 45(5):606-13. PubMed ID: 16368733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacoeconomics of coxib therapy.
    Cantor SB
    J Pain Symptom Manage; 2002 Jul; 24(1 Suppl):S28-37. PubMed ID: 12204485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.
    Sostres C; Gargallo CJ; Arroyo MT; Lanas A
    Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):121-32. PubMed ID: 20227026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies.
    Lanas A; Hunt R
    Ann Med; 2006; 38(6):415-28. PubMed ID: 17008305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands.
    Herings RM; Klungel OH
    Pharmacoeconomics; 2001; 19(6):655-65. PubMed ID: 11456213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs.
    Bennett K; Teeling M; Feely J
    Eur J Clin Pharmacol; 2003 Nov; 59(8-9):645-9. PubMed ID: 12942226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs.
    Pilotto A; Franceschi M; Vitale DF; Zaninelli A; Masotti G; Rengo F; ;
    Aliment Pharmacol Ther; 2005 Jul; 22(2):147-55. PubMed ID: 16011673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study.
    Sebaldt RJ; Petrie A; Goldsmith CH; Marentette MA
    Am J Manag Care; 2004 Nov; 10(11 Pt 1):742-50. PubMed ID: 15623264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.